Kyle Vaccaro

Nov 26, 2024 | biorxiv.org | Juliet Allen |Anna Meglan |Kyle Vaccaro |José Manuel Velarde

AbstractMacrophages hold tremendous promise as effectors of cancer immunotherapy, but the best strategies to provoke these cells to attack tumors remain unknown. Here, we evaluated the therapeutic potential of targeting two distinct macrophage immune checkpoints: CD47 and CD24. We found that antibodies targeting these antigens could elicit maximal levels of phagocytosis when combined together in vitro.

May 1, 2024 | jci.org | Gordon Mills |Marilyne Labrie |Kyle Vaccaro |Aaron N. Hata

AbstractTargeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro- or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins.